RWLK VS ABBV Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend

Performance

RWLK
10/100

RWLK returned -33.16% in the last 12 months. Based on SPY's performance of -21.08%, its performance is below average giving it a score of 10 of 100.

ABBV
100/100

ABBV returned -4.80% in the last 12 months. Based on SPY's performance of -20.59%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

RWLK
80/100

5 analysts offer 12-month price targets for RWLK. Together, they have an average target of 3, the most optimistic target put RWLK at 3 within 12-months and the most pessimistic has RWLK at 3.

ABBV
68/100

20 analysts offer 12-month price targets for ABBV. Together, they have an average target of 158.73, the most optimistic target put ABBV at 200 within 12-months and the most pessimistic has ABBV at 127.

Sentiment

RWLK
70/100

RWLK had a bullish sentiment score of 69.59% across Twitter and StockTwits over the last 12 months. It had an average of 16.27 posts, 18.18 comments, and 54.60 likes per day.

ABBV
71/100

ABBV had a bullish sentiment score of 71.15% across Twitter and StockTwits over the last 12 months. It had an average of 130.21 posts, 1,504.50 comments, and 7,664.76 likes per day.

Technicals

RWLK
10/100

RWLK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

ABBV
11/100

ABBV receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

RWLK
10/100

RWLK has missed earnings 12 times in the last 20 quarters.

ABBV
100/100

ABBV has missed earnings 0 times in the last 20 quarters.

Profit

RWLK
10/100

Out of the last 20 quarters, RWLK has had 0 profitable quarters and has increased their profits year over year on 0 of them.

ABBV
80/100

Out of the last 20 quarters, ABBV has had 18 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

RWLK
44/100

RWLK has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

ABBV
47/100

ABBV has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Dividend

RWLK

"Dividend" not found for RWLK

ABBV
100/100

ABBV's most recent dividend was $0.97 per share, based on a share price of $138.93. It was a payout ratio of 53.19% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

ReWalk Robotics Ltd Summary

Nasdaq / RWLK
Healthcare
Medical Devices
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.

ABBVIE INC. Summary

New York Stock Exchange / ABBV
Healthcare
Drug Manufacturers - General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.